venBio Partners

Founded 2009
Founders Corey Goodman Kurt von Emster Robert Adelman

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 51
Average round size
info
The average size of a deal this fund participated in
$51M
Portfolio companies 36
Rounds per year 4.25
Lead investments 16
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.29
Exits 21
Key employees 1
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Biopharma
Summary

The venture was found in North America in United States. The leading representative office of defined VC is situated in the San Francisco.

We can highlight the next thriving fund investment areas, such as Genetics, Therapeutics. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has specific favorite in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Among the most popular portfolio startups of the fund, we may highlight Adaptimmune, Harmony Biosciences, Checkmate Pharmaceuticals. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund.

The current fund was established by Corey Goodman, Kurt von Emster, Robert Adelman. The overall number of key employees were 1.

The fund is constantly included in 2-6 investment rounds annually. The real fund results show that this VC is 18 percentage points more often commits exit comparing to other companies. Opposing the other organizations, this venBio Partners works on 12 percentage points more the average amount of lead investments. The top activity for fund was in 2018. The common things for fund are deals in the range of 50 - 100 millions dollars. The average startup value when the investment from venBio Partners is 100-500 millions dollars. The top amount of exits for fund were in 2019.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the venBio Partners, startups are often financed by Remeditex Ventures, Sofinnova Investments, F-Prime Capital. The meaningful sponsors for the fund in investment in the same round are Vivo Capital, F-Prime Capital, Sofinnova Investments. In the next rounds fund is usually obtained by Vivo Capital, F-Prime Capital, Cormorant Asset Management.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of venBio Partners:
Typical Co-investors
venBio Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after venBio Partners:

Funds with similar focus

Funds from United States, San Francisco
Funds with similar focus located in United States, San Francisco:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Rho Ventures United States, New York
BOOST Programs France, Paris
SanomaVentures Netherlands, Noord-Holland
1440 Foundation United States, Saratoga
KoppiCatch Finland, Helsinki
Powerhouse Ventures United States, Oakland
Activa Capital France, Paris
Green Arrow Capital Italy, Milan
Formula Ventures Israel, Tel Aviv
Accelerator Fund United States, Pittsburgh
AARD Capital -
Kitano Investments -
Legion Capital United States, Cheyenne
Yamaguchi Technology Licensing Organization Japan, Tokyo
Hongfei Zichan China, Chongming
Relan Global Management LLC United States, Los Gatos
Bucketplace -
PYJ-Dynasty Venture Fund United States, Santa Barbara
Shoutou Zichan China, Zhuhai
SanomaVentures Netherlands, Noord-Holland
eSeed Ventures -

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Neurogastrx

Biotechnology
Health Care
Health Diagnostics
Pharmaceutical
1
$60M26 Aug 2021 United States, " United States"}

Fog Pharmaceuticals

Biotechnology
Health Care
Pharmaceutical
1
$107M11 Jan 2021 United States, Cambridge

Tallac Therapeutics

Biotechnology
Health Care
Therapeutics
1
$62M01 Dec 2020 United States, " United States"}

Elevation Oncology

Biopharma
Biotechnology
Health Care
Life Science
Pharmaceutical
1
$65M18 Nov 2020 United States, New York

Stargazer Pharmaceuticals

Manufacturing
Pharmaceutical
1
$57M09 Nov 2020 United States, Boston

RayzeBio

Biotechnology
Health Care
Medical Device
Pharmaceutical
1
$45M14 Oct 2020 United States, San Diego

Biopharma
Biotechnology
Health Care
Medical
1
$25M14 Sep 2020 United States, San Francisco

Artiva Biotherapeutics

Biotechnology
Life Science
Therapeutics
1
$78M26 Jun 2020 United States, San Diego

Checkmate Pharmaceuticals

Biotechnology
Medical Device
Pharmaceutical
Therapeutics
1
$85M10 Jun 2020 United States, Cambridge
News
RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer

– RayzeBio, Inc. announced a $108m Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X.
– Also participating were all of Rayze’s existing investors: venBio Partners, Versant Ventures, Samsara BioCapital, Redmile Group, Viking Global Investors, Cormorant Asset Management, OrbiMed, LifeSci Venture Partners, Logos Capital, Alexandria Venture Investments, and others.
– The targeted radiopharmaceuticals field represents a highly clinically validated modality that, until recently, has been underappreciated.
– With over $258m of capital raised since the company first debuted in the second half of 2020, RayzeBio has rapidly expanded its team, infrastructure, capabilities, and pipeline.

Ventyx Biosciences Raises $114M in Funding

– Ventyx is an Encinitas, California-based clinical-stage biotechnology company advancing a broad pipeline of potent and selective small-molecule drug candidates to treat inflammatory diseases and autoimmune disorders.
– The company raised $114m in Series C funding.
– The round was led by venBio Partners alongside new investors, including Third Point, RTW Investments, LP, Janus Henderson Investors, Wellington Management, OrbiMed, Surveyor Capital (a Citadel company), Farallon Capital, Vivo Capital, Logos Capital, Qiming Venture Partners USA, Cormorant Asset Management, and participation from founding investor New Science Ventures.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent venBio Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: